Seiyu Issues Apology for Providing 282 False Pharmaceutical Seller Certificates
This article was originally published in PharmAsia News
In a case involving major supermarket chain Seiyu’s issuance of false certificates of registered sellers of pharmaceuticals, the company admitted Nov. 6 that 282 certificates in at least 19 regions in Japan contained false information and apologized for causing a major inconvenience to customers.
You may also be interested in...
Teligent has followed through with plans to condense its outstanding shares to raise their value and maintain a stock-exchange listing. Meanwhile, the company revealed a sizeable loss for the first quarter of this year, as it gave the latest on its warning letter-stricken facility in Buena, New Jersey.
Celltrion's Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the World Health Organization.
Fresenius Kabi’s Idacio biosimilar adalimumab rival to Humira will from the start of June be marketed in Germany by Medac, following a deal between the two companies.